hsa-miR-4328在急性早幼粒细胞白血病中的下调及靶基因预测

IF 0.5 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
O. T. Lupu, B. Popescu, Elena Avram, M. Dragomir, Gheorghe Dănuț Cimponeriu, Ioana Mighiu, Silvia Aposteanu, D. Coriu
{"title":"hsa-miR-4328在急性早幼粒细胞白血病中的下调及靶基因预测","authors":"O. T. Lupu, B. Popescu, Elena Avram, M. Dragomir, Gheorghe Dănuț Cimponeriu, Ioana Mighiu, Silvia Aposteanu, D. Coriu","doi":"10.2478/rrlm-2022-0022","DOIUrl":null,"url":null,"abstract":"Abstract Introduction: Acute promyelocytic leukemia (APL) is defined by the PML-RARA fusion gene. APL treatment can have significant side effects, therefore the development of optimal therapeutic options is crucial. Although the study of miRNAs is still in its infancy, it has been shown that these molecules are involved in the pathogenesis of neoplasms by modulating the expression of target genes. miRNAs can be considered possible biomarkers in APL and can be used as therapeutic targets or as markers for the therapeutic response. Objectives: The purpose of this study was to determine whether differentially expressed putative miRNAs that have RARA as a target gene could be considered reliable biomarkers for APL. Methods: Using bioinformatics tools, a panel of 6 miRNAs with possible tropism for the RARA gene was selected from miRDB. We evaluated their expression levels in samples from patients with APL (n=20) or from healthy subjects without mutations in genes associated with leukemia or myeloproliferative diseases (n=21). Results: All 6 putative miRNAs were identified using electrophoresis (hsamir-4299, hsa-mir-4328, hsa-mir-7851-3p, hsa-mir-6827-5p, hsa-mir-6867-5p, hsa-mir-939-5p). Of the six miRNAs, hsa-mir-4328 is deeply downregulated in subjects diagnosed with APL compared to healthy subjects, whereas hsa-mir-4299 and hsa-mir-7851-3p show small differences in expression between the two study groups, but without statistical significance. Our results suggest that hsa-mir-4328 may have a role in the pathogenesis of APL and may represent a new biomarker for this type of leukemia. Key Words: miRNA, APL, leukemia, bioinformatics.","PeriodicalId":49599,"journal":{"name":"Revista Romana De Medicina De Laborator","volume":"63 1","pages":"261 - 272"},"PeriodicalIF":0.5000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Downregulation of hsa-miR-4328 and target gene prediction in Acute Promyelocytic Leukemia\",\"authors\":\"O. T. Lupu, B. Popescu, Elena Avram, M. Dragomir, Gheorghe Dănuț Cimponeriu, Ioana Mighiu, Silvia Aposteanu, D. Coriu\",\"doi\":\"10.2478/rrlm-2022-0022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Introduction: Acute promyelocytic leukemia (APL) is defined by the PML-RARA fusion gene. APL treatment can have significant side effects, therefore the development of optimal therapeutic options is crucial. Although the study of miRNAs is still in its infancy, it has been shown that these molecules are involved in the pathogenesis of neoplasms by modulating the expression of target genes. miRNAs can be considered possible biomarkers in APL and can be used as therapeutic targets or as markers for the therapeutic response. Objectives: The purpose of this study was to determine whether differentially expressed putative miRNAs that have RARA as a target gene could be considered reliable biomarkers for APL. Methods: Using bioinformatics tools, a panel of 6 miRNAs with possible tropism for the RARA gene was selected from miRDB. We evaluated their expression levels in samples from patients with APL (n=20) or from healthy subjects without mutations in genes associated with leukemia or myeloproliferative diseases (n=21). Results: All 6 putative miRNAs were identified using electrophoresis (hsamir-4299, hsa-mir-4328, hsa-mir-7851-3p, hsa-mir-6827-5p, hsa-mir-6867-5p, hsa-mir-939-5p). Of the six miRNAs, hsa-mir-4328 is deeply downregulated in subjects diagnosed with APL compared to healthy subjects, whereas hsa-mir-4299 and hsa-mir-7851-3p show small differences in expression between the two study groups, but without statistical significance. Our results suggest that hsa-mir-4328 may have a role in the pathogenesis of APL and may represent a new biomarker for this type of leukemia. Key Words: miRNA, APL, leukemia, bioinformatics.\",\"PeriodicalId\":49599,\"journal\":{\"name\":\"Revista Romana De Medicina De Laborator\",\"volume\":\"63 1\",\"pages\":\"261 - 272\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Romana De Medicina De Laborator\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2478/rrlm-2022-0022\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Romana De Medicina De Laborator","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/rrlm-2022-0022","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 1

摘要

摘要简介:急性早幼粒细胞白血病(APL)由PML-RARA融合基因定义。APL治疗可能有明显的副作用,因此开发最佳治疗方案至关重要。虽然对mirna的研究还处于起步阶段,但已经证明这些分子通过调节靶基因的表达参与肿瘤的发病机制。mirna可以被认为是APL中可能的生物标志物,可以用作治疗靶点或治疗反应的标记物。目的:本研究的目的是确定以RARA为靶基因的差异表达的推定mirna是否可以被认为是APL的可靠生物标志物。方法:利用生物信息学工具,从miRDB中筛选出6个可能对RARA基因有趋向性的mirna。我们在APL患者(n=20)或与白血病或骨髓增生性疾病相关基因无突变的健康受试者(n=21)的样本中评估了它们的表达水平。结果:通过电泳鉴定了所有6种推测的mirna (hsamir-4299, hsa-mir-4328, hsa-mir-7851-3p, hsa-mir-6827-5p, hsa-mir-6867-5p, hsa-mir-939-5p)。在这六种mirna中,与健康受试者相比,确诊为APL的受试者中hsa-mir-4328表达深度下调,而hsa-mir-4299和hsa-mir-7851-3p在两个研究组之间表达差异较小,但无统计学意义。我们的研究结果表明,hsa-mir-4328可能在APL的发病机制中发挥作用,并可能代表这类白血病的新生物标志物。关键词:miRNA, APL,白血病,生物信息学
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Downregulation of hsa-miR-4328 and target gene prediction in Acute Promyelocytic Leukemia
Abstract Introduction: Acute promyelocytic leukemia (APL) is defined by the PML-RARA fusion gene. APL treatment can have significant side effects, therefore the development of optimal therapeutic options is crucial. Although the study of miRNAs is still in its infancy, it has been shown that these molecules are involved in the pathogenesis of neoplasms by modulating the expression of target genes. miRNAs can be considered possible biomarkers in APL and can be used as therapeutic targets or as markers for the therapeutic response. Objectives: The purpose of this study was to determine whether differentially expressed putative miRNAs that have RARA as a target gene could be considered reliable biomarkers for APL. Methods: Using bioinformatics tools, a panel of 6 miRNAs with possible tropism for the RARA gene was selected from miRDB. We evaluated their expression levels in samples from patients with APL (n=20) or from healthy subjects without mutations in genes associated with leukemia or myeloproliferative diseases (n=21). Results: All 6 putative miRNAs were identified using electrophoresis (hsamir-4299, hsa-mir-4328, hsa-mir-7851-3p, hsa-mir-6827-5p, hsa-mir-6867-5p, hsa-mir-939-5p). Of the six miRNAs, hsa-mir-4328 is deeply downregulated in subjects diagnosed with APL compared to healthy subjects, whereas hsa-mir-4299 and hsa-mir-7851-3p show small differences in expression between the two study groups, but without statistical significance. Our results suggest that hsa-mir-4328 may have a role in the pathogenesis of APL and may represent a new biomarker for this type of leukemia. Key Words: miRNA, APL, leukemia, bioinformatics.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista Romana De Medicina De Laborator
Revista Romana De Medicina De Laborator MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
0.31
自引率
20.00%
发文量
43
审稿时长
>12 weeks
期刊介绍: The aim of the journal is to publish new information that would lead to a better understanding of biological mechanisms of production of human diseases, their prevention and diagnosis as early as possible and to monitor therapy and the development of the health of patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信